Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most statements match the provided NUCALA prescribing information (indications, EGPA, IL-5 mechanism, subcutaneous route, q4-week dosing, injection-site reactions, headache, hypersensitivity warning signs). Minor label mismatches/unsupported generalizations were identified, particularly around broader eosinophilic conditions wording and the specificity of flare reduction wording.
Category Scores
Accurate Statements
Mepolizumab (brand name Nucala) is a monoclonal antibody used for certain eosinophil-driven inflammatory diseases.
Mechanism and labeled indications across asthma/CRSwNP/COPD/EGPA/HES with eosinophilic phenotype; mechanism includes IL-5 antagonist leading to reduced eosinophils (Sections 1, 12.1).
Mepolizumab is used in adults and some pediatric patients for severe eosinophilic asthma.
Severe asthma indicated for add-on maintenance in adult and pediatric patients aged 6 years and older (Section 1.1). Pediatric use described (Section 8.4).
Mepolizumab is used for eosinophilic granulomatosis with polyangiitis (EGPA).
EGPA indicated for adult patients (Section 1.4).
Mepolizumab targets interleukin-5 (IL-5) signaling.
Mepolizumab is an IL-5 antagonist; binds to IL-5 inhibiting its bioactivity (Section 12.1).
IL-5 signaling is involved in the growth and survival of eosinophils.
Label states IL-5 major cytokine for growth/differentiation, recruitment, activation, and survival of eosinophils (Section 12.1).
By blocking IL-5 activity, mepolizumab reduces blood and tissue eosinophil levels.
Pharmacodynamics: following subcutaneous administration, blood eosinophils reduced to similar magnitude (Section 12.2); mechanism reduces production and survival of eosinophils (Section 12.1). Label support for “blood eosinophils” is explicit; “tissue” is not explicitly stated in provided excerpts.
Mepolizumab is administered by injection under the skin (subcutaneous).
“NUCALA is for subcutaneous use only” (Section 2.1). Also administration route emphasized (Section 14.1).
Mepolizumab is administered on a regular schedule, commonly every 4 weeks for many indications.
Table 1 shows 100 mg every 4 weeks for severe asthma (and pediatric 6-11/12-17 per label), CRSwNP, COPD; and 300 mg every 4 weeks for EGPA and HES (Sections 2.1 and Table 1).
Benefit from mepolizumab is measured clinically across treatment cycles rather than after a single dose.
Clinical studies described over treatment periods and outcomes such as exacerbation reduction, remission/relapse time, and HES flare incidence over weeks/months (Section 14 across indications).
Commonly reported side effects of mepolizumab include injection-site reactions.
Injection site reactions occurred at a rate of 8% vs 3% placebo in severe asthma example (Section 6.1).
Mepolizumab can cause other adverse effects depending on the patient population and underlying disease.
Label describes adverse reactions including hypersensitivity and herpes zoster, and notes adverse reactions are described in greater detail in other sections and identified post-approval; also safety varies by population/indication (Sections 5, 6, and 8).
Patients should seek urgent care for signs of severe allergic reaction with mepolizumab, such as facial swelling, trouble breathing, or hives.
Hypersensitivity reactions including angioedema and urticaria have occurred (Section 5.1). (Label excerpt does not explicitly list “facial swelling” phrasing or “trouble breathing,” but these map to angioedema and bronchospasm included in the label.)
Mepolizumab is marketed as Nucala.
Drug name: NUCALA with active ingredient mepolizumab (entire provided label context).
Unsupported Statements
Mepolizumab is used in other eosinophilic conditions listed in its prescribing information.
The label excerpts provided list specific labeled conditions (severe asthma, CRSwNP, COPD, EGPA, HES). The claim is generic (“other eosinophilic conditions”) and is not explicitly stated as such in the provided sections; however, it is consistent with the listed indications. Scored as partially supported, but not explicitly supported as phrased.
By blocking IL-5 activity, mepolizumab helps lower the frequency of disease flares in IL-5/eosinophil-driven conditions.
The label excerpts provide specific outcomes (e.g., fewer exacerbations in asthma/COPD, greater time in remission and longer time to first relapse in EGPA, reduced HES flare incidence). The claim is broader and not explicitly phrased as “frequency of disease flares” across all IL-5/eosinophil-driven conditions in the provided excerpts.
Commonly reported side effects of mepolizumab include headache.
The provided label excerpts do not list headache as a commonly reported adverse reaction. (Injection-site reactions and herpes zoster/hypersensitivity are explicitly described; headache is not shown in the supplied text.)
Mepolizumab reduces blood and tissue eosinophil levels.
The provided excerpt explicitly supports reduction of blood eosinophils (Section 12.2). Tissue eosinophil reduction is not explicitly stated in the provided excerpts.
Contradictions
Important Omissions
Statement that NUCALA is not indicated for acute bronchospasm/status asthmaticus/COPD acute exacerbations.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
A key safety-related label limitation (not for acute bronchospasm/exacerbations) was omitted, and one adverse-effect claim (headache as commonly reported) is not supported by the provided excerpts. Other major safety elements (hypersensitivity warning signs) were generally aligned.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Unsubstantiated claim that headache is a common side effect, plus an omission of the label limitation regarding use for acute symptoms.
Suggested Improvement
Remove or qualify the “headache commonly reported” claim unless supported by the provided label text; add that NUCALA should not be used to treat acute bronchospasm/status asthmaticus or acute COPD exacerbations, consistent with the label limitations of use (Section 1.1/1.3/5.2 excerpts).